Faeth Therapeutics, Inc.

NASDAQ: FTH · Healthcare · Biotechnology

PublicHQ Rockville, MD · MontgomeryCIK 0001829802Reports USD

#1 of 1,420 Healthcare companies by revenue

EA Score

——

FH 50DQ —GM —SS 59

v0.1 · 35/100 weight · pillars only

↑ balance-sheet leverage, market scale · ↓ filing timeliness, return on equity

Methodology →

Revenue TTM

-$4.9M

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$21.1M

Employees

as of 2026-08-20

Market cap

$853.5M

as of 2026-08-20

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$21.1M-$21.1M2025

Operating income-$22.3M-$22.3M2025

Total assets$22.9M$22.9M2025

Liabilities$4.3M$4.3M2025

Equity$18.6M$18.6M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Faeth Therapeutics, Inc.’s financial profile?

Faeth Therapeutics, Inc. earned -$21.1M in FY2025 net income.

Peers · Healthcare

Lumexa Imaging Holdings, Inc. Common Stock——Sana Biotechnology, Inc.——Annexon, Inc.——Aura Biosciences, Inc.——Climb Bio, Inc.——Bright Minds Biosciences Inc.——

Neighbors

Montgomery →

Lockheed Martin Corporation$75.0B81B+Marriott International, Inc.$26.2B82B+United Therapeutics Corporation$3.2B92A Host Hotels & Resorts, Inc.$6.1B69B AGNC Investment Corp.——Federal Realty Investment Trust$1.3B75B+

Key facts

CEOAnand Parikh

SectorHealthcare

IndustryBiotechnology

HeadquartersRockville, MD

ExchangeNASDAQ: FTH

Employees29

IPO date2014-08-11

Latest filings

10-Q2026-08-04 8-K2026-08-04 8-K2026-07-23 8-K2026-06-18 8-K2026-06-15 8-K2026-06-10 8-K2026-05-22 8-K2026-05-21

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.